
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
EMD Millipore expands its Provantage upstream bioproduction services into North America.
This expansion allows EMD Millipore's North American customers to access the same services European customers have received at the company's GMP biodevelopment center in Martillac, France.
Source:






